News

Home / News and Events

September 16, 2024 | Featured

Tharimmune Acquires Global Exclusive License to Develop INT-023, an Oral Anti-TNFα mAb for Treatment of Autoimmune Diseases

May 28, 2024 | Featured

Bio-Sourcing, Ciloa and Intract Pharma launch €3.4M EU project in inflammatory indications with €1.9M subsidies from EUREKA Eurostars

November 08, 2022 | Featured

Intract Announces Publication on Pre-clinical Data with Merck & Co. on Colon Targeted Delivery of JAK Inhibitor using Phloral® Technology

September 16, 2022 | Featured

Elasmogen and Intract Enter License Agreement for Soteria® and Phloral® Technologies

April 01, 2022 | Featured

Intract Pharma Appoints Dr Vipul Yadav as Chief Executive Officer

September 27, 2021 | Featured

Bio-Thera Solutions and Intract Pharma Enter Global Collaboration and License Agreement for Soteria® and Phloral® Drug Delivery Technologies to Enable Development of Oral Antibody Medicines

April 22, 2021 | Featured

Intract Pharma and NIBEC Enter into an Agreement to Develop a Novel Oral Peptide Therapy for Treatment of Ulcerative Colitis.

April 01, 2021 | Featured

Intract Pharma Enters into Research Collaboration with Ferring Pharmaceuticals to Evaluate Oral delivery of Monoclonal Antibodies for Treatment of Chronic Gastrointestinal Diseases

August 20, 2020 | Featured

Intract Pharma Limited and Celltrion Group announce collaboration for development of oral Infliximab.

Page: 1 2 3 4 >

Copyright © 2018 Intract Pharma

A site by: Web Design London